Evidence map›Paper›PMID 33321871›Full record

ArticleBrain sciences2020

The Association between the Usage of Non-Steroidal Anti-Inflammatory Drugs and Cognitive Status: Analysis of Longitudinal and Cross-Sectional Studies from the Global Alzheimer's Association Interactive Network and Transcriptomic Data.

Robert Morris, Kyle Armbruster, Julianna Silva, Daniel James Widell, Feng Cheng

Open access · goldAbstract read
In one paragraph

Article in Brain sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Effects ofFrontiers in nutrition · 2026
    Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Robert MorrisDepartment of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL 33613, USA.
Kyle ArmbrusterBiomedical Science Program, College of Art and Science, University of South Florida, Tampa, FL 33620, USA.
Julianna SilvaBiomedical Science Program, College of Art and Science, University of South Florida, Tampa, FL 33620, USA.
Daniel James WidellBiomedical Science Program, College of Art and Science, University of South Florida, Tampa, FL 33620, USA.
Feng ChengDepartment of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL 33613, USA.ORCID 0000-0003-3619-8090
University of South Florida · US

Funding

Identification of Potential Drug-drug Interactions in Alzheimer's Disease PatientsR03AG070536 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI CHENG, FENG · 2020 to 2021
$150k
Alzheimer's Association GEENA-QNIA NIH HHS 1R03AG070536-01NIA NIH HHS R03 AG070536
6 · The paper itself

Abstract

The degenerative cognitive and physical decline of Alzheimer patients, coupled with the extensive psychological and economic tolls imposed on family members that serve as caretakers, necessitate the discovery of effective cures and preventative measures for age-related cognitive depreciation. In the journey of Alzheimer's disease treatment discovery, several cross-sectional and longitudinal studies have delineated a noticeable association between the use of nonsteroidal anti-inflammatory drugs (NSAIDs), a class of low-cost drugs with minimal side effects, and the alleviation of age-related memory impairment. In this study, four datasets (two cross-sectional and two longitudinal studies) derived from the Global Alzheimer's Association Interactive Network (GAAIN) were analyzed. The significant association between the usage of NSAIDs and better cognitive status was observed. The results agree with the findings of previous studies that the use of NSAIDs may be beneficial in the early stages of Alzheimer's disease. Transcriptomic data show that ibuprofen treatment results in upregulation of several genes involved in arachidonic acid metabolism including PPARγ, Cyp4a12b, Cyp2c66, and Cyp2c37 in the hippocampus. The increase in conversion of arachidonic acid into anti-inflammatory 16C and 18C dicarboxylic acids as well as epoxyeicosatrienoic acids may play a role in reducing the risk of Alzheimer's disease development.

Indexed as

Alzheimer’s diseasearachidonic acidGAAINmemorymicroarrayNSAID

Identifiers

PMID33321871
PMCPMC7763310
OpenAlexW3113281813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.